Psychedelic therapy

Psychedelic therapy is an approach in which a carefully supported drug experience is used as a means of psychological or spiritual change. Its defining claim is that the experience itself can matter as much as, or more than, the chemical: a powerful session may unsettle habitual perspectives and help a person see life differently. That claim grew from attempts to treat alcohol dependence, changed as researchers listened to patients’ accounts, and persists in modern trials whose encouraging results remain provisional.

From simulated delirium to the experience itself

In Saskatchewan, Humphry Osmond and Abram Hoffer initially tested a deliberately startling idea: that one high-dose LSD session could produce a controlled delirium resembling delirium tremens, shocking a person with alcohol dependence into sobriety. Over the next decade, they treated more than seven hundred people. They reported that roughly half became sober and stayed sober for at least several months, and regarded the approach as more effective than other available therapies. The result was not only a proposed treatment but a new emphasis in psychopharmacology: what mattered was not simply the substance administered, but what the person experienced under its influence.

That emphasis ran against behaviorism, which treated observable outcomes as primary and subjective experience as scientifically suspect. Yet the session reports did not fit the researchers’ original theory. Hallucinations, paranoia, and anxiety sometimes occurred, but many volunteers described a sense of unity with the world, increased sensory awareness, new perspectives on philosophy or religion, and greater sensitivity to others. For patients treated at Weyburn hospital, the experience often seemed closer to transcendence or spiritual revelation than to temporary insanity. Aldous Huxley’s account of his mescaline experience strengthened Osmond and Hoffer’s doubts about classifying such states as psychosis. The mismatch between their delirium theory and patients’ reports helped shift the therapeutic question from how to induce madness to how an unusual state might enable change.

The treatment room as part of the treatment

Osmond and Hoffer also came to see that the circumstances of a session shaped what happened within it. A supportive, empathetic therapist could help prevent a frightening experience; the sterile hospital room and disengaged clinician, by contrast, might contribute to the very reactions researchers then interpreted as drug effects. Although the phrase set and setting became associated with Timothy Leary’s later work at Harvard, Osmond and Hoffer were already recognizing the importance of a person’s expectations and environment.

The treatment that took shape in the mid-1950s generally involved a single high dose, usually of LSD, in comfortable surroundings. The subject lay on a couch, often wearing eyeshades and listening to music, while one or two therapists remained present but spoke little. Rather than directing the experience moment by moment, the arrangement encouraged an inward journey, with the hope that it might produce a profound, conversion-like change. In this model, preparation and atmosphere were not decorative additions to pharmacology: they helped organize the experience and the person’s response to it.

Al Hubbard helped make that principle tangible. Though neither a scientist nor a formally trained therapist, he understood that an impersonal, brightly lit hospital room was poorly suited to an experience he hoped would be revelatory. He brought pictures, music, flowers, and diamonds into treatment rooms, using objects and attention to shape the session or redirect it when it became frightening. One alcoholic treated by Hubbard recalled being handed roses during an LSD session and asked first to hate them, then to love them. As the patient described the flowers withering and returning in greater brilliance, he connected the experience to his own relationships and recognized that some of his difficulties with people came from his own perspective. Hubbard’s practice anticipated a central therapeutic insight: in an altered state, words, music, and objects can carry unusual suggestive force, so the guide’s conduct and the treatment space require care.

Replication, risk, and the need for a container

The Saskatchewan results became influential enough that the provincial government helped make LSD therapy a standard treatment option for alcohol dependence. But the findings seemed too good to be true to some members of the Canadian medical establishment. In the early 1960s, Toronto’s Addiction Research Foundation attempted a more tightly controlled replication, seeking to isolate the drug’s effects from other variables. Clinicians placed patients in neutral rooms, avoided engaging with them apart from administering questionnaires, and sometimes restrained or blindfolded them. The results did not match the Saskatchewan reports; several volunteers had terrifying experiences. Critics concluded that the therapy performed poorly under rigorous controls, while its proponents argued that the stripped-down conditions had removed a crucial part of the treatment. Both conclusions captured something important: the drug could not be evaluated separately from the conditions in which it was given, and those conditions could also go wrong.

This tension remains visible in contemporary underground practice. The psychedelic underground described in the book is a dispersed network of guides and therapists, some risking their professional licenses by working with controlled substances. Its practitioners draw on varied professional, religious, and alternative traditions, but share a body of practices intended to make sessions safer and more purposeful. A draft charter describes making experiences of unitive or nondual consciousness more accessible; it also recognizes meditation, breathwork, and fasting alongside psychoactive substances as possible routes to such states.

The network’s practical documents address the vulnerability that makes guidance consequential. Its ethical code calls for disclosure of risks, informed consent, confidentiality, attention to participants’ safety and health, safeguards against a guide’s self-promotion, and accommodation regardless of ability to pay. Its guidelines cover mental and physical preparation, drug interactions, intention, the possible stages and difficulties of a session, and post-session integration. Taken together, these protocols make the guide responsible not only for what happens during the experience but also for the conditions under which a participant enters and interprets it. The work is presented as requiring a cultural vessel—rules, agreements, and rituals that can contain an experience understood as powerful and potentially destabilizing.

Modern clinical evidence and its limits

Modern clinical protocols preserve elements of the earlier approach while placing them inside formal research. In the NYU cancer trial described in the book, Patrick Mettes was scheduled for preparatory talking sessions and two dosing days: one with a high dose of niacin as an active placebo, the other with twenty-five milligrams of psilocybin. Each session was expected to occupy most of a day. He would lie on a couch wearing eyeshades and listening to a carefully chosen playlist, while two sitters remained present and available but largely quiet. His therapist, Tony Bossis, advised him to trust and let go, and to move toward frightening material rather than flee from it. The procedure made concrete the older principles of preparation, music, eyeshades, and attentive company, while specifying the drug, comparison condition, and responsibilities of the treatment team.

Results reported in December 2016 from the NYU and Johns Hopkins cancer studies renewed professional interest. Across the two trials, about 80 percent of patients showed clinically significant reductions in anxiety and depression, with effects lasting at least six months; the intensity of reported mystical experience closely correlated with symptom reduction. The combined studies involved only eighty subjects, however, and the results would need larger-scale replication before they could support regulatory changes. A separate feasibility study at Imperial College, led by Robin Carhart-Harris in David Nutt’s laboratory, gave psilocybin to twelve people with treatment-resistant depression without a control group. All showed improvement after a week, and two-thirds were depression-free; after the study expanded to twenty participants, six remained in remission at six months while others had relapsed to varying degrees. The findings offered a promising signal, not conclusive proof of a durable treatment.

That distinction matters because early psychedelic research has repeatedly invited expansive claims. Small studies may select volunteers likely to respond and provide them with unusually attentive, highly trained therapists; expectation and placebo effects can also influence outcomes. The evidence described in the book supports neither a claim that psychedelics cure many disorders nor a dismissal of their potential. It instead leaves an important question open: if one kind of therapy appears to help with conditions as different as addiction, depression, and cancer-related anxiety, perhaps some of those conditions share features that the treatment reaches. Psychedelic therapy’s history makes that question inseparable from another: whether change arises from the drug alone, or from the experience shaped by preparation, setting, care, and subsequent integration.